Prophylactic central neck dissection in differentiated thyroid cancer : risks and benefits in a population with a high rate of tumour recurrence
BACKGROUND: The role of prophylactic central neck dissection (pCND) in differentiated thyroid cancer (DTC) is still controversial.
METHODS: In a cohort of 274 DTC cN0 patients with a high rate of tumour recurrence, who underwent total thyroidectomy with or without pCND, clinical and histopathological features were retrospectively analysed.
RESULTS: In our cohort, no clinical or histopathological features are able to predict the presence of central lymph node metastases (CLNM) at diagnosis, which instead represents the only variable significantly associated with a higher risk of long-term tumour relapse, independently from age, sex, BMI and radioiodine treatment (OR=1.03, CI95% 1.002-1.074, p<0.05). Moreover, our study demonstrates that pCND does not significantly increase the risk of post-surgical complications.
CONCLUSIONS: In our setting, pCND could have a key role in the management of DTC. The risks and benefits of pCND should be evaluated for each population to make the most appropriate therapeutic choice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Minerva endocrinology - (2022) vom: 30. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raia, Melissa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.23736/S2724-6507.22.03892-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346934893 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346934893 | ||
| 003 | DE-627 | ||
| 005 | 20240217232106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23736/S2724-6507.22.03892-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM346934893 | ||
| 035 | |a (NLM)36177956 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raia, Melissa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prophylactic central neck dissection in differentiated thyroid cancer |b risks and benefits in a population with a high rate of tumour recurrence |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: The role of prophylactic central neck dissection (pCND) in differentiated thyroid cancer (DTC) is still controversial | ||
| 520 | |a METHODS: In a cohort of 274 DTC cN0 patients with a high rate of tumour recurrence, who underwent total thyroidectomy with or without pCND, clinical and histopathological features were retrospectively analysed | ||
| 520 | |a RESULTS: In our cohort, no clinical or histopathological features are able to predict the presence of central lymph node metastases (CLNM) at diagnosis, which instead represents the only variable significantly associated with a higher risk of long-term tumour relapse, independently from age, sex, BMI and radioiodine treatment (OR=1.03, CI95% 1.002-1.074, p<0.05). Moreover, our study demonstrates that pCND does not significantly increase the risk of post-surgical complications | ||
| 520 | |a CONCLUSIONS: In our setting, pCND could have a key role in the management of DTC. The risks and benefits of pCND should be evaluated for each population to make the most appropriate therapeutic choice | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Mele, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Loredana |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'era, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Samà, Maria T |e verfasserin |4 aut | |
| 700 | 1 | |a Marzullo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Aimaretti, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Garzaro, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Aluffi Valletti, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Minerva endocrinology |d 2021 |g (2022) vom: 30. Sept. |w (DE-627)NLM309915252 |x 2724-6116 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:30 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23736/S2724-6507.22.03892-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 30 |c 09 | ||